Key facts
- This page summarizes Danielle Watson's Form 4 filing for HeartSciences Inc. (HSCS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jan 2025, 17:17.
Danielle Watson - 16 Jan 2025 Form 4 Insider Report for HeartSciences Inc. (HSCS)
- Reporting relationship
- Chief Financial Officer and Treasurer
- Issuer ticker
- HSCS
- Reported as of
- 16 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jan 2025, 17:17:06 UTC
- Prior SEC filing
- 22 Mar 2023
- Next SEC filing
- 11 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Simpson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Danielle Watson filed Form 4 for HeartSciences Inc. (HSCS) on 21 Jan 2025.
Change
- Previous filing in this sequence was filed on 22 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HSCS
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +9,000
- Change %
- Price
- Shares after
- 9,000
- Date
- 16 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,000
- Exercise price
- $3.33
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.
Footnote F2
One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of April 16, 2026 (the "Subsequent Vesting Date") and thereafter on each successive three-month anniversary of the Subsequent Vesting Date for the next seven fiscal quarters, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration. As of the date of this filing, such regulatory clearance has not been received.
Footnote F3
These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement.
SEC remarks
Chief Financial Officer and Treasurer